Merck's diabetic eye-disease drug hits primary goal but faces commercial doubts

Merck announced results from a pivotal trial of its ophthalmology candidate remigromig, aimed at treating diabetic macular edema.

The study achieved its primary endpoint, demonstrating that remigromig was non-inferior to the existing therapy, Lucentis. However, the complete data set introduced questions about the drug’s overall commercial viability.

Analysts note that while the primary outcome is encouraging, the lingering uncertainties could temper enthusiasm among investors and may influence Merck’s next steps in development.